Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Immunovant, Inc.IMVT · Entity 3632 | Chief Legal Officer | October 07, 2026 | October 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Immunovant, Inc.
Report date October 07, 2026 · Filed October 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 175,218 |
Reported balance
After 2026-10-07 transaction · row 1
1 source rowRow 1 · 2026-10-07 · Sale · Disposed 1,327 · Balance 175,218 F1: On April 1, 2025, the holder was granted 50,787 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 3, 2025, of which 3,174 of these RSUs vested on October 1, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.58 - $32.30 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: On April 1, 2025, the holder was granted 50,787 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 3, 2025, of which 3,174 of these RSUs vested on October 1, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.58 - $32.30 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 07, 2026 Filed Oct 9, 2026 21:05 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 1,327 | $32.06 | $42,543.62 |
DisclosureSEC source: 0001779707-26-000009 · wk-form4_1791579901.xml · nonDerivative · entry 1 Van Tuyl Christopher · CIK 0001779707 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,218 F1 · shares: On April 1, 2025, the holder was granted 50,787 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 3, 2025, of which 3,174 of these RSUs vested on October 1, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.58 - $32.30 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| September 23, 2026 Filed Sep 25, 2026 20:05 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 2,846 | $36.36 | $103,480.56 |
DisclosureSEC source: 0001764013-26-000108 · wk-form4_1790366730.xml · nonDerivative · entry 1 Van Tuyl Christopher · CIK 0001779707 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 176,545 F1 · shares: On December 16, 2024, the holder was granted 109,956 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on December 18, 2024, of which 6,872 of these RSUs vested on September 16, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.35 - $36.66 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| July 08, 2026 Filed Jul 10, 2026 20:13 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 63 | $39.99 | $2,519.37 |
DisclosureSEC source: 0001764013-26-000082 · wk-form4_1783714421.xml · nonDerivative · entry 2 Van Tuyl Christopher · CIK 0001779707 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 179,391 F1 · shares: On April 1, 2025, the holder was granted 50,787 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 3, 2025, of which 3,174 of these RSUs vested on July 1, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.92 - $40.03 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| July 08, 2026 Filed Jul 10, 2026 20:13 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 1,143 | $39.53 | $45,182.79 |
DisclosureSEC source: 0001764013-26-000082 · wk-form4_1783714421.xml · nonDerivative · entry 1 Van Tuyl Christopher · CIK 0001779707 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 179,454 F1 · shares: On April 1, 2025, the holder was granted 50,787 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 3, 2025, of which 3,174 of these RSUs vested on July 1, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.91 - $39.89 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| June 26, 2026 Filed Jun 26, 2026 23:45 UTC | Immunovant, Inc. IMVT · Entity 3632 | Exercise / conversionStock Option (right to buy) · Derivative | 17,824 | $0.00 Strike: $15.20 | $0.00 |
DisclosureSEC source: 0001764013-26-000073 · wk-form4_1782517498.xml · derivative · entry 4 Van Tuyl Christopher · CIK 0001779707 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,707 Underlying: Common Stock · 17,824 shares Expires 2035-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Award of stock options to purchase Common Shares with a grant date of April 1, 2025. The shares underlying the option vest as to 25% on April 1, 2026, with the remainder vesting in 36 successive substantially equal monthly installments over three years thereafter, subject to the Reporting Person's continued service to the Issuer as of such date. Read SEC document |
| June 26, 2026 Filed Jun 26, 2026 23:45 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 2,842 | $38.96 | $110,724.32 |
DisclosureSEC source: 0001764013-26-000073 · wk-form4_1782517498.xml · nonDerivative · entry 3 Van Tuyl Christopher · CIK 0001779707 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,597 F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.82 - $39.15 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| June 26, 2026 Filed Jun 26, 2026 23:45 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 14,982 | $38.19 | $572,162.58 |
DisclosureSEC source: 0001764013-26-000073 · wk-form4_1782517498.xml · nonDerivative · entry 2 Van Tuyl Christopher · CIK 0001779707 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 183,439 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.75 - $38.70 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| June 26, 2026 Filed Jun 26, 2026 23:45 UTC | Immunovant, Inc. IMVT · Entity 3632 | Exercise / conversionCommon Stock | 17,824 | $15.20 | $270,924.80 |
DisclosureSEC source: 0001764013-26-000073 · wk-form4_1782517498.xml · nonDerivative · entry 1 Van Tuyl Christopher · CIK 0001779707 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 198,421 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 18, 2026 Filed Jun 22, 2026 20:02 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 2,634 | $35.39 | $93,217.26 |
DisclosureSEC source: 0001779707-26-000006 · wk-form4_1782158542.xml · nonDerivative · entry 1 Van Tuyl Christopher · CIK 0001779707 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,597 F1 · shares: On December 16, 2024, the holder was granted 109,956 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on December 18, 2024, of which 6,872 of these RSUs vested on June 16, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| April 08, 2026 Filed Apr 10, 2026 20:05 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 5,165 | $24.83 | $128,246.95 |
DisclosureSEC source: 0001779707-26-000004 · wk-form4_1775851530.xml · nonDerivative · entry 1 Van Tuyl Christopher · CIK 0001779707 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 183,231 F1 · shares: On April 1, 2025, the holder was granted 50,787 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 3, 2025, of which 12,696 of these RSUs vested on April 1, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.54 - $25.39 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| April 07, 2026 Filed Apr 9, 2026 20:17 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantStock Option (right to buy) · Derivative | 59,820 | $0.00 Strike: $24.61 | $0.00 |
DisclosureSEC source: 0001764013-26-000036 · wk-form4_1775765844.xml · derivative · entry 2 Van Tuyl Christopher · CIK 0001779707 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,820 Underlying: Common Stock · 59,820 shares Expires 2036-04-07 F2 · derivative.exercise_date: These options were granted pursuant to the Plan. The shares underlying the options will vest as to 25% of the total shares on April 1, 2027 and the balance will vest in thirty-six (36) successive substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date. Read SEC document |
| April 07, 2026 Filed Apr 9, 2026 20:17 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantCommon Stock | 41,343 | $0.00 | $0.00 |
DisclosureSEC source: 0001764013-26-000036 · wk-form4_1775765844.xml · nonDerivative · entry 1 Van Tuyl Christopher · CIK 0001779707 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 188,396 F1 · shares: These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest as to 25% of the total shares on April 1, 2027 and the balance will vest in twelve (12) successive substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date. Read SEC document |
| March 18, 2026 Filed Mar 20, 2026 20:11 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 2,877 | $24.97 | $71,838.69 |
DisclosureSEC source: 0001764013-26-000015 · wk-form4_1774037475.xml · nonDerivative · entry 1 Van Tuyl Christopher · CIK 0001779707 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 147,053 F1 · shares: On December 16, 2024, the holder was granted 109,956 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on December 18, 2024, of which 6,872 of these RSUs vested on March 16, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| December 18, 2025 Filed Dec 19, 2025 21:05 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 2,284 | $27.38 | $62,535.92 |
DisclosureSEC source: 0001764013-25-000163 · wk-form4_1766178313.xml · nonDerivative · entry 2 Van Tuyl Christopher · CIK 0001779707 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 149,930 F1 · shares: On December 16, 2024, the holder was granted 109,956 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on December 18, 2024, of which 27,489 of these RSUs vested on December 16, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.25 - $27.52 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| December 18, 2025 Filed Dec 19, 2025 21:05 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 8,529 | $26.78 | $228,406.62 |
DisclosureSEC source: 0001764013-25-000163 · wk-form4_1766178313.xml · nonDerivative · entry 1 Van Tuyl Christopher · CIK 0001779707 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 152,214 F1 · shares: On December 16, 2024, the holder was granted 109,956 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on December 18, 2024, of which 27,489 of these RSUs vested on December 16, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.23 - $27.22 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:55 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantStock Option (right to buy) · Derivative | 71,531 | $0.00 Strike: $15.20 | $0.00 |
DisclosureSEC source: 0001764013-25-000059 · wk-form4_1743713694.xml · derivative · entry 2 Van Tuyl Christopher · CIK 0001779707 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,531 Underlying: Common Stock · 71,531 shares Expires 2035-04-01 F2 · derivative.exercise_date: The shares underlying the options will vest as to 25% of the shares on April 1, 2026 and the remainder will vest in 36 substantially equal monthly installments over three years thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:55 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantCommon Stock | 50,787 | $0.00 | $0.00 |
DisclosureSEC source: 0001764013-25-000059 · wk-form4_1743713694.xml · nonDerivative · entry 1 Van Tuyl Christopher · CIK 0001779707 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,743 F1 · shares: These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest as to 25% of the units on April 1, 2026, and the remainder will vest in substantially equal installments on a quarterly basis over three years thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date. Read SEC document |
| December 16, 2024 Filed Dec 18, 2024 22:02 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantStock Option (right to buy) · Derivative | 137,446 | $0.00 Strike: $27.63 | $0.00 |
DisclosureSEC source: 0001764013-24-000204 · wk-form4_1734559363.xml · derivative · entry 2 Van Tuyl Christopher · CIK 0001779707 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,446 Underlying: Common Stock · 137,446 shares Expires 2034-12-16 F2 · derivative.exercise_date: This option was granted pursuant to the Issuer's 2019 Equity Incentive Plan. The shares underlying the option will vest as to 25% of the shares on December 16, 2025, and the remainder will vest in 12 successive substantially equal quarterly installments over three years thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date. Read SEC document |
| December 16, 2024 Filed Dec 18, 2024 22:02 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantCommon Stock | 109,956 | $0.00 | $0.00 |
DisclosureSEC source: 0001764013-24-000204 · wk-form4_1734559363.xml · nonDerivative · entry 1 Van Tuyl Christopher · CIK 0001779707 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,956 F1 · shares: These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest as to 25% of the units on December 16, 2025, and the remainder will vest in 12 successive substantially equal quarterly installments over three years thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.